Peanut Allergy
Last reviewed: March 2026
The Most Dangerous Food Allergy
Peanut allergy is the most common cause of fatal food-induced anaphylaxis in the United States and one of the most feared food allergies worldwide. It affects approximately 2.5% of children in the US, a prevalence that has more than tripled since 2000 for reasons that are still being studied. Unlike many childhood food allergies, peanut allergy is typically lifelong, with only about 20% of allergic children outgrowing it. The allergy can cause reactions ranging from mild symptoms like hives and stomach discomfort to severe, life-threatening anaphylaxis involving difficulty breathing, a drop in blood pressure, rapid pulse, dizziness, and loss of consciousness. Anaphylaxis from peanuts can progress rapidly and can be fatal within minutes if not treated with epinephrine. The threshold dose for triggering a reaction varies greatly between individuals, with some people reacting to milligrams of peanut protein while others can tolerate larger amounts before symptoms appear. This variability makes peanut allergy particularly challenging to manage, as even trace amounts in shared equipment or inadvertent contact can pose risks for the most sensitive individuals.
How Peanut Allergy Works: The Immune Mechanism
Peanut allergy is an IgE-mediated immune response in which the body mistakenly identifies peanut proteins as dangerous invaders. The major allergenic proteins in peanuts are designated Ara h 1 through Ara h 17, with Ara h 1, Ara h 2, Ara h 3, and Ara h 6 being the most clinically significant. Ara h 2 is considered the most potent peanut allergen and is the best predictor of clinical reactivity. During initial sensitization, which often occurs through skin exposure (particularly through broken skin such as eczema) rather than ingestion, the immune system produces IgE antibodies specific to peanut proteins. These antibodies attach to mast cells and basophils throughout the body. Upon subsequent exposure to peanut, the proteins bind to the IgE antibodies on these cells, triggering degranulation and the rapid release of histamine, leukotrienes, and other inflammatory mediators. This cascade produces the symptoms of an allergic reaction. Component-resolved diagnostics, which measure IgE to specific Ara h proteins rather than whole peanut extract, can help allergists better predict the likelihood and severity of clinical reactions and distinguish true peanut allergy from cross-reactive sensitization to birch pollen.
Hidden Peanut Sources and Cross-Contact Risks
Peanuts and peanut-derived ingredients appear in many foods where they might not be expected. Asian cuisine (Chinese, Thai, Vietnamese, Indonesian) frequently uses peanuts, peanut oil, and peanut-based sauces. African and Indian cuisines also incorporate peanuts in stews, sauces, and snacks. Baked goods from bakeries are high-risk due to shared equipment. Ice cream shops pose cross-contact risks from shared scoops and toppings. Chili and Cincinnati-style chili may use peanut butter as a thickener. Egg rolls, spring rolls, and pad Thai commonly contain peanuts. Candy, particularly chocolate bars, nougat, and pralines, frequently contains peanuts or is manufactured on shared lines. Marzipan is almond-based but may be processed near peanuts. Some unexpected sources include pet food (many dog treats contain peanut butter), bird seed, and craft supplies in schools. Arachis oil is another name for peanut oil. Peanut flour is increasingly used as a protein booster in smoothies and energy bars. "May contain peanuts" or "processed in a facility that also processes peanuts" advisory statements are voluntary but should be taken seriously. Cross-contact can occur in restaurants through shared fryers, grills, and utensils, and even through airborne peanut particles in confined spaces like airplanes.
The Severity Spectrum and Recognizing Anaphylaxis
Peanut allergic reactions span a wide spectrum of severity, and the same individual may experience different levels of reaction at different times depending on factors like the amount consumed, whether they have exercised, concurrent illness, or alcohol consumption. Mild reactions may involve localized symptoms such as hives around the mouth, tingling lips, mild nausea, or a few spots of urticaria. Moderate reactions can include widespread hives, facial swelling, abdominal cramping, vomiting, or diarrhea. Severe reactions, or anaphylaxis, involve multiple organ systems and can include throat tightening, difficulty swallowing, shortness of breath, wheezing, a significant drop in blood pressure, rapid or weak pulse, dizziness, and loss of consciousness. Biphasic reactions, in which symptoms resolve and then return hours later without additional exposure, occur in approximately 5-20% of anaphylactic events. Every person with a peanut allergy should carry two epinephrine auto-injectors (such as EpiPen, Auvi-Q, or generic alternatives) at all times. Epinephrine should be administered at the first sign of a severe reaction, not withheld in hopes that symptoms will resolve. After administering epinephrine, the person should be taken to an emergency department for monitoring, as biphasic reactions can occur up to 12 hours later.
Peanut-Free Schools and Institutional Policies
The management of peanut allergy in schools and public institutions has been a topic of significant debate. Many schools have implemented peanut-free policies, including designated peanut-free lunch tables, classroom bans on peanut-containing snacks, and in some cases, school-wide peanut bans. These policies aim to protect allergic students from accidental exposure, particularly young children who may not yet be able to advocate for themselves or recognize symptoms. Supporters argue that schools have a duty to provide a safe learning environment for all students. Critics contend that total bans create a false sense of security and may not account for imperfect compliance. The current consensus among allergy organizations is that a combination of strategies is most effective: education for staff, students, and parents about food allergies; strict handwashing policies after eating; no sharing of food or utensils; supervised eating areas; trained staff with access to epinephrine; and individualized allergy action plans. Section 504 of the Rehabilitation Act and the Americans with Disabilities Act require schools to make reasonable accommodations for students with food allergies. Parents should work with the school to develop a comprehensive allergy management plan, including a Food Allergy and Anaphylaxis Emergency Care Plan signed by the child's physician.
Cross-Reactivity: Peanuts, Tree Nuts, and Legumes
Peanuts are legumes, botanically related to beans, lentils, chickpeas, and soybeans, not to tree nuts. However, the cross-reactivity between peanuts and other legumes is relatively low. Studies show that clinical cross-reactivity (actual allergic reaction, as opposed to just positive test results) between peanut and other legumes is approximately 5%. Most peanut-allergic individuals can safely eat beans, lentils, and other legumes, though testing by an allergist is recommended. Lupine (lupin), a legume commonly used in European baked goods and pasta, is a notable exception with higher cross-reactivity to peanut. Soy cross-reactivity with peanut is also low in clinical practice, and most peanut-allergic individuals tolerate soy without issues. The relationship between peanut and tree nut allergy is more complex. While peanuts and tree nuts are not botanically related, approximately 25-40% of peanut-allergic individuals also have a tree nut allergy. This may be due to co-sensitization rather than true cross-reactivity. Allergists often test for tree nut allergies in peanut-allergic patients and may recommend avoidance of tree nuts if sensitization is found. Some families choose to avoid all tree nuts as a precaution, particularly for young children, while others include tree nuts that have been confirmed safe through testing.
Refined Peanut Oil: Usually Safe but Controversial
Highly refined peanut oil is generally considered safe for most peanut-allergic individuals because the refining process removes virtually all peanut protein, which is the component that triggers allergic reactions. The FDA exempts highly refined oils from allergen labeling requirements for this reason. Studies have demonstrated that most peanut-allergic individuals can consume highly refined peanut oil without reaction. However, there are important caveats. Cold-pressed, expelled, or extruded peanut oils (sometimes called "gourmet" peanut oil) retain significant amounts of peanut protein and are NOT safe for peanut-allergic individuals. The distinction between refined and unrefined oils is critical and not always clear from labeling. Some restaurants, particularly those serving Asian cuisine, use peanut oil for frying and may not know whether their oil is highly refined or crude. Given the potentially life-threatening nature of peanut allergy, many allergists recommend that their patients avoid all peanut oil as a precaution, especially when the refinement level cannot be verified. Chick-fil-A, which cooks in refined peanut oil, is frequently cited in discussions about this topic, and many peanut-allergic individuals report eating there without issues, though individual decisions should be made in consultation with an allergist.
Early Introduction: The LEAP Study and Prevention Guidelines
One of the most groundbreaking changes in food allergy management in recent decades came from the LEAP (Learning Early About Peanut Allergy) study, published in 2015. This landmark randomized controlled trial demonstrated that early introduction of peanut-containing foods to high-risk infants (those with severe eczema and/or egg allergy) between 4 and 11 months of age reduced the risk of developing peanut allergy by approximately 81% compared to strict avoidance. This finding overturned decades of guidance that had recommended delaying introduction of allergenic foods. Based on the LEAP study and subsequent research, the NIAID issued updated guidelines in 2017 recommending that high-risk infants be introduced to peanut-containing foods as early as 4-6 months of age, after evaluation by an allergist that may include skin prick testing. Moderate-risk infants (those with mild to moderate eczema) should be introduced to peanut around 6 months. Low-risk infants (no eczema or food allergy) can have peanut introduced freely as part of the complementary diet. Peanut should be given in age-appropriate forms such as thinned peanut butter, peanut puffs, or peanut powder mixed into pureed foods, never as whole peanuts or chunky peanut butter, which pose a choking hazard. Regular, sustained consumption is important, as the LEAP-On follow-up study showed that continued regular intake maintained protection.
Oral Immunotherapy: Palforzia and Beyond
Oral immunotherapy (OIT) for peanut allergy represents a major advance in treatment options. In January 2020, the FDA approved Palforzia (peanut allergen powder), the first FDA-approved treatment for peanut allergy. Palforzia is designed for children and adolescents ages 4-17 with a confirmed peanut allergy. The treatment involves a carefully structured protocol: an initial dose escalation day in a medical facility, followed by up-dosing over approximately 6 months (with each dose increase given under medical supervision), and then a daily maintenance dose taken at home. The goal is not to enable free consumption of peanut but rather to raise the threshold of reactivity, reducing the risk of severe reactions from accidental exposure. Clinical trials showed that after completing the Palforzia protocol, 67% of participants could tolerate 600mg of peanut protein (roughly two peanuts) compared to 4% in the placebo group. However, OIT is not without risks. Allergic reactions during treatment are common, including gastrointestinal symptoms, and anaphylaxis can occur. Eosinophilic esophagitis (EoE) has been reported in some patients. The treatment requires daily dosing indefinitely, and protection may wane if doses are missed. Beyond Palforzia, research into epicutaneous immunotherapy (a peanut patch called Viaskin Peanut), sublingual immunotherapy (drops under the tongue), and biologic medications like omalizumab combined with OIT continue to advance.
Emotional and Social Impact of Peanut Allergy
The psychological burden of peanut allergy extends far beyond the physical risk. Studies consistently show that food allergy, particularly peanut allergy due to its severity and unpredictability, significantly impacts quality of life for both the allergic individual and their family. Children with peanut allergy report higher levels of anxiety, social isolation, and bullying compared to their non-allergic peers. Food allergy bullying is alarmingly common, with studies showing that approximately one-third of food-allergic children have been bullied because of their allergy, including having allergens deliberately waved in their faces, thrown at them, or snuck into their food. Adolescents face particularly high risk because they are more likely to eat away from home, engage in risk-taking behavior, and feel embarrassed about carrying epinephrine or asking about ingredients. Tragically, most fatal food allergy reactions occur in teenagers and young adults. Parents of peanut-allergic children frequently report elevated anxiety, hypervigilance, and stress related to managing the allergy, which can affect family dynamics and the child's developing sense of autonomy. Mental health support, including cognitive behavioral therapy, can be beneficial. Organizations like FARE offer peer support programs, and connecting with other food allergy families can reduce feelings of isolation and provide practical coping strategies.
International Labeling and Global Considerations
Peanut allergy labeling requirements vary significantly around the world, posing challenges for travelers and for understanding imported foods. In the United States, FALCPA (2004) requires clear labeling of peanut as one of the major allergens, using the common name "peanut" in the ingredient list or in a separate "Contains" statement. The European Union requires labeling of 14 major allergens, including peanuts, with emphasis on both pre-packaged and non-pre-packaged foods (including restaurant meals). In the UK, Natasha's Law (2021) requires full ingredient labeling on all foods pre-packaged for direct sale, including items prepared on-site. Canada, Australia, and Japan all mandate peanut allergen labeling. However, precautionary allergen labeling ("may contain peanuts") remains voluntary in most countries and is inconsistently applied, making it difficult for consumers to assess actual risk. Some countries use different common names or terms for peanut: "groundnut" in the UK and parts of Asia, "arachide" in French-speaking countries, and "mani" in Spanish-speaking countries. When traveling internationally, carrying a food allergy translation card in the local language is essential. Several organizations and apps provide these cards in dozens of languages. Always research the local cuisine and common ingredients at your destination before traveling, and identify nearby medical facilities in case of emergency.
Medical Disclaimer: This information is sourced from peer-reviewed medical literature and authoritative health organizations. It is for educational purposes only and should not replace advice from your healthcare provider. Always consult with a board-certified allergist about your specific condition.